March 13, 2024
Loading...
You are here:  Home  >  'Amgen'  -  Page 51
Latest

Amgen suffers setback as patent office refuses to review competitor’s drug

By   /  Thursday, January 14th, 2016  /  East Ventura County, Health Care & Life Science, Latest news  /  Comments Off on Amgen suffers setback as patent office refuses to review competitor’s drug

The U.S. Patent and Trademark Office handed Amgen a potential setback Jan. 14 when it declined to review two patent expiration dates on a competitor’s drug. In June, Thousand Oaks-based biotech giant Amgen asked the agency to review two formulation patents for Humira, made by Chicago-based competitor AbbVie, arguing that the patents should not have Read More →

Latest

Settlement ends Amgen drug kickback saga

By   /  Thursday, January 7th, 2016  /  East Ventura County, Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Settlement ends Amgen drug kickback saga

A drug kickback program is finally behind Amgen, the Thousand Oaks-based pharmaceutical giant. Louisville, K.Y.-based PharMerica was the last of three companies to settle lawsuits relating to Amgen allegedly paying kickbacks to PharMerica and another company to prescribe patients the anemia drug Aranesp. PharMerica settled the suit for $2.5 million in December, Louisville Business First Read More →

Latest

Amgen increases dividend to $1 per share

By   /  Tuesday, December 15th, 2015  /  Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Amgen increases dividend to $1 per share

Amgen increased its yearly dividend 27 percent this year to $1 per share. Previously, the dividend had been 79 cents per share for the Thousand Oaks-based biotech giant. Shares jumped after news of the 27-cent dividend broke. The announcement was made just after the markets closed at 1:11 p.m. Amgen closed the trading day up Read More →

Latest

Amgen reacquires rights to sell 3 drugs worldwide

By   /  Monday, December 14th, 2015  /  Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Amgen reacquires rights to sell 3 drugs worldwide

Amgen reacquired all rights to sell three drugs worldwide on Dec. 14. The Thousand Oaks-based biotech giant said it reacquired the rights to Prolia, Vectibix and Xgeva in 48 ccountries from British pharmaceutical company GlaxoSmithKline. The agreement includes large countries like Australia, China and Brazil. Prolia is designed to raise bone density in people with Read More →

Latest

Novartis biosimilar works as well as Amgen’s Neulasta

By   /  Monday, December 7th, 2015  /  Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Novartis biosimilar works as well as Amgen’s Neulasta

Swiss pharmaceutical Novartis announced Monday that a copycat version of Amgen’s Neulasta works just as well to prevent a condition that can lead to infection in women with breast cancer. Neulasta stimulates white blood cell production in the body, which helps the body fight cancer. Novartis’ new drug is part of a new class of Read More →

Latest

Amgen seeks European OK of biosimilar drug, partners with Merck on studies

By   /  Friday, December 4th, 2015  /  East Ventura County, Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Amgen seeks European OK of biosimilar drug, partners with Merck on studies

Amgen announced two developments Dec. 4 that should help the Thousand Oaks-based biotech giant compete. Amgen said it is seeking approval from the European Medicines Agency for ABP 501, a biosimilar drug similar to Humira. Amgen also announced a partnership with New Jersey-based pharmaceutical Merck to partner in a non-Hodgkins lymphoma study using drugs from Read More →

Latest

Amgen bipolar about biosimilars

By   /  Friday, December 4th, 2015  /  Health Care & Life Science, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen bipolar about biosimilars

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.